$CLBT

Learn Why The Bull Case For Cellebrite DI (CLBT) Could Change Following Secure Cloud Approval

Cellebrite DI (CLBT) announced its Guardian cloud platform received a PROTECTED-level IRAP assessment for Australian public sector use, and launched the C TEK backpack kit for military forensics. These developments could impact contract structures, deployment costs, and long-term demand from government clients. The company projects $787.4M revenue and $122.0M earnings by 2029, implying 15.3% yearly revenue growth. Analysts' fair value estimates range from $12.50 to $15.36, with the current share

Original reporting
Published Sep 8, 2026, 3:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 9, 2026, 9:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$CLBT
Bullish
medium confidence
Mentioned
$CLBT
Relevance
6/10
AlphAI data visualization · based on simplywall.st
Decision brief

The 30-second read

$CLBTBullishMed
01

Why it matters

The IRAP assessment validates security compliance, potentially unlocking new contracts, while the C TEK kit expands product depth into defense field operations.

02

Market read

New compliance approval and hardware launch could drive growth in the digital forensics market.

03

What to watch

Potential delays in procurement cycles and competition from other forensics providers could limit upside.

Relevance 6/10Novelty 6/10Timing: today

Background

Cellebrite DI provides software and services for legally sanctioned investigations, targeting law enforcement and national security customers.

Company-level read

Ticker impact

$CLBTBullishMedium confidence
Context

Cellebrite DI announced its Guardian cloud platform passed an IRAP assessment for Australian public sector customers and introduced the C TEK backpack kit for military field use.

Expected impact

Potential upside if contracts materialize, but margin pressure possible from hardware logistics.

Evidence & confidence

First disclosure of IRAP approval and new hardware offering provides fresh growth catalyst, though execution risk remains.

Market effects

Highlights growing demand for cloud-based digital evidence solutions in government and defense sectors.

May strengthen Australian public sector tech spend and influence similar contracts in other allied markets.

Signals broader trend of digital forensics moving to cloud platforms worldwide.

Counterpoint

Margin compression from hardware logistics could offset revenue gains, and reliance on large government contracts remains a risk.

Key entities

  • Cellebrite DI

    Developer of digital evidence and forensics solutions.

Related articles

$CLBTMedAI 8/10

Cellebrite (CLBT) Q2 2026 Earnings Call Transcript

Cellebrite (CLBT) announced Shiv Ramji as its new CEO, replacing Tom Hogan. The company missed Q2 revenue expectations due to delayed large transactions and lower-than-expected ARR uplift. Despite this, they raised their full-year adjusted EBITDA target. Ramji outlined plans to improve sales execution and forecasting discipline. The company sees growth in new products and federal business, with a 25% increase in Defense and Intelligence ARR.

$CLBTMedAI 8/10

Why Cellebrite DI (CLBT) Is Down 30.4% After Cutting 2026 Outlook And Announcing CEO Transition

Cellebrite DI Ltd. reported half-year 2026 results and cut its full-year revenue outlook to US$555 million to US$561 million, implying 17% to 18% growth. The company also announced a CEO transition, with Shiven Ramji succeeding Thomas E. Hogan. The guidance reduction, weaker profitability, and delayed large government contracts contributed to a sharp stock drop.

$CLBTMedAI 8/10

Cellebrite DI Ltd. Q2 2026 Earnings Call Summary

Cellebrite DI Ltd. reported Q2 2026 results below expectations, citing delayed large transactions and procurement hurdles tied to foreign entity status. Full-year ARR guidance was cut to $550m–$560m, while adjusted EBITDA was raised to $153m–$159m. Management said Insights installed base reached 65% and Genesis launched with $400k ARR.

$CLBTMed

Cellebrite (CLBT) Stock Rebounds As ARR Grows But Outlook Cools

Simply Wall St reports Cellebrite (CLBT) shares rose about 3% after results despite a prior 30% drop. Q2 revenue was US$131.1m (up from US$113.3m), while ARR was US$508m (up from US$420m). Management raised full-year adjusted EBITDA margin guidance to the high 20s but trimmed ARR outlook to US$550m to US$560m.